녹내장 치료 시 점안약 치료 후 안부작용에 관한 연구
The Study of Ocular Side Effects after the Use of Anti-Glaucoma Topical Medication
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 녹내장 환자에서 녹내장 점안약의 개수, 종류, 점안기간이 녹내장 점안약 사용 시 발생하는 부작용에 미치는 영향에 대해서 알아보고자 하였다. 대상과 방법: 528명의 녹내장 환자를 대상으로 녹내장 점안약 사용 후 발생하는 부작용에 대해 설문조사를 시행하였다. 점수화되어나타나는 부작용의 정도와 약의 개수, 종류, 점안기간 간의 관계에 대해서 분석하였다. 결과: 사용하고 있는 점안약의 개수가 많을수록 부작용의 정도가 더 심하였으며(p˂0.01), 점안기간이 증가함에 따라 녹내장 점안약에의한 부작용을 더 많이 호소하였다(p˂0.01). 1개의 약을 사용하는 환자 중 OcucarpineⓇ을 사용하는 경우에서 부작용이 가장 심했으나2개 또는 3개의 약을 사용하는 경우에는 약제의 종류에 따른 부작용의 정도는 차이가 없었다. 결론: 녹내장 점안약을 사용하는 환자에서 점안 약의 개수가 많거나 점안기간이 오래된 환자에서 부작용의 발생이 증가하고, 1개의녹내장 점안약을 사용하는 환자에서 OcucarpineⓇ을 사용하는 경우 부작용이 심하였고 2개 이상의 약을 사용하는 경우 종류에 따라부작용의 정도는 큰 차이를 보이지 않았다.
Abstract
Purpose: To investigate the influence of number and type of side effects as well as treatment period after the use of anti-glaucoma eye drops in patients with glaucoma. Methods: A survey was conducted regarding the severity of ocular side effects after the use of anti-glaucoma eye drops in 528 patients with glaucoma. Side effects after using the eye drops included irritability, blurred vision, foreign body sensation,hyperemia, pinpricking sensation, itching, discomfort, pain, tearing, dry eye, and pigmentation. We analyzed the results to investigate the influence of number and type of side effects as well as treatment period. Results: The side effects after the use of anti-glaucoma eye drops were more severe and frequent in the patient groups using more than 1 eye drop (p < 0.01) and in the patients with longer treatment period (p < 0.01). Among patients using 1 eye drops, side effects developed frequently in patients using Ocucarpine®. Conclusions: In patients with glaucoma, using more than 1 anti-glaucoma eye drop or having a longer treatment period resulted in more side effects. Similaryly, patients using only 1 eye drop of Ocu-carpine® induced more side effects.
참고문헌 (24)
- Quigley HA, "Number of people with glaucoma worldwide", Br J Ophthalmol, 80, pp.389~393 (1996)
- Goldmann H, "Applanation tonometry", Ophthalmologica, 134, pp.221~242 (1957)
- Shazly TA, "Comparison of intraocular pressure-lowering effect of every night versus every other night dosing of bimatoprost 0.03%", J Ocul Pharmacol Ther, 27, pp.369~371 (2011)
- Collaborative Normal-Tension Glaucoma Study Group, "The effectiveness of intraocular pressure reduction in the treatment of normal- tension glaucoma", Am J Ophthalmol, 126, pp.498~505 (1998)
- The AGIS Investigators, "The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration", Am J Ophthalmol, 130, pp.429~440 (2000)
- Katsanos A, "Bimatoprost and bimatoprost", timolol fixed combination in patients with open-angle glaucoma and ocular hypertension, 2011, pp.27, 67~71
- Schuman JS, "Antiglaucoma medications: a review of safety and tolerability issues related to their use", Clin Ther, 22, pp.167~208 (2000)
- Pfister RR, "effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study", Invest Ophthalmol, 15, pp.246~259 (1976)
- Burstein NL, "Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas", Invest Ophthalmol Vis Sci, 19, pp.308~313 (1980)
- Tripathi BJ, "Cytotoxicity of ophthalmic preservatives on human corneal epithelium", Lens Eye Toxic Res, 9, pp.361~375 (1992)
- Alm A, "Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group", Ophthalmology, 102, pp.1743~1752 (1995)
- Burtein NL, "Corneal cytotoxicity of topically applied drugs, vehicles and preservatives", Surv Ophthalmol, 25, pp.15~30 (1980)
- Pisella PJ, "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", Br J Ophthalmol, 86, pp.418~423 (2002)
- Lavin MJ, "The influence of prior therapy on the success of trabeculectomy", Arch Ophthalmol, 108, pp.1543~1548 (1990)
- Richter CU, "The development of encapsulated filtering blebs", Ophthalmology, 95, pp.1163~1168 (1988)
- Broadway D, "Adverse effects of topical antiglaucomatous medications on the conjunctiva", Br J Ophthalmol, 77, pp.590~596 (1993)
- Broadway DC, "Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery", Arch Ophthalmol, 112, pp.1446~1454 (1994)
- Ashburn FS Jr, "Compliance with ocular therapy", Surv Ophthalmol, 24, pp.237~248 (1980)
- Ahn DH, "Factors affecting compliance with prescribed eyedrops for glaucoma", Korean J Ophthalmol Soc, 39, pp.2145~2151 (1998)
- Beckers HJ, "Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction", Graefes Arch Clin Exp Ophthalmol, 246, pp.1485~1490 (2008)
- Dreer LE, "Determinants of medication adherence to topical glaucoma therapy", J Glaucoma, 21, pp.234~240 (2012)
- Robin A, "Compliance and adherence in glaucoma management", Indian J Ophthalmol, 59(Suppl), pp.S93~S96 (2011)
- Granström PA, "Glaucoma patient not compliant with their drug therapy: clinical and behavioural aspects", Br J Ophthalmol, 66, pp.464~470 (1982)
- Berdy GJ, "Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects", Arch Ophthalmol, 110, pp.528~532 (1992)